The treatment of allergic rhinitis is shown to improve co-existing conditions including conjunctivitis, asthma, sinusitis, otitis media with effusion (fluid in the middle ear) and sleep disorders according to an international expert at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla. "Allergic rhinitis often co-exists with numerous co-morbid disorders and should be treated in the context of systemic allergic disease, " said Prof. Ruby Pawankar, M.D., Ph.D, Nippon Medical School, Tokyo, Japan. "Allergic rhinitis is a global health problem that causes major illness and disability worldwide. Impairment of quality of life is seen in both adults and children with allergic rhinitis. It affects them at school and work. Patients also have sleep disorders, emotional problems, decreased cognitive functioning impairment in activities and social functioning, " Dr. Pawankar said. Current estimates indicate that more than 50 million people in the United States suffer from allergic rhinitis - allergies that are characterized by sneezing, nasal congestion, runny nose and watery eyes.
ISTA Pharmaceuticals Highlights Bepreve TM Clinical Data At The 2009 Annual Meeting Of The American College Of Allergy, Asthma Immunology ACAAI
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced additional results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies. These results were presented in poster sessions at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Miami Beach, FL. In a poster presentation titled, "Treatment of Ocular Itching with Bepotastine Besilate Ophthalmic Solution 1.5% for Subjects with More Severe Itching Response in a Conjunctival Allergen Challenge (CAC) Clinical Model of Allergic Conjunctivitis, " integrated results from two Phase 3 studies demonstrated Bepreve 1.5% was as effective in suppressing ocular itching in patients with more severe itching as in patients with all grades of ocular itching. A total of 157 patients were enrolled in two 7-week, masked, randomized, placebo-controlled CAC clinical studies (1 single site, 1 multi-site). 113 patients exhibited bilateral ocular itching grades greater than or equal to 3 at screening during study visit 2.
Asthmatx, Inc. presented the results of a series of studies investigating the effectiveness and safety of bronchial thermoplasty delivered by the Alair® System, and how this new procedure will impact allergy practices, this past weekend in a poster at the 2009 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), in Miami Beach, Fla. The poster, titled "Where Could Bronchial Thermoplasty (BT) Fit Into Your Allergy Practice? Lessons Learned from Multiple Bronchial Thermoplasty Clinical Trials, " highlighted the clinical results from three randomized clinical trials, which investigated bronchial thermoplasty's effectiveness as a treatment option for patients with severe asthma. Bronchial thermoplasty is a non-drug procedure developed to treat adults with severe asthma and is designed to provide improved asthma quality of life and control that lasts for at least one year. Bronchial thermoplasty delivered by the Alair System uses thermal energy to reduce the amount of smooth muscle in the lungs, which is associated with airway constriction in asthma patients.
Researchers in Belgium have discovered that a type of immune cell previously not well understood helped mice from developing an allergic reaction to certain airborne particles that can trigger asthma: they suggest these cells, called lung interstitial macrophages (IMs), may have the same effect in humans. The study was the work of Fabrice Bureau and colleagues, at the University of LiÃ¨ge, Belgium, and was published online on 9 November in the Journal of Clinical Investigation. Our respiratory tract is continually bombarded by microbe-derived molecules. Their arrival triggers numerous immune system responses, and the arrival of one particular molecule, lipopolysaccharide, commonly known as LPS, triggers asthma in some people. However, what is not well understood is why, when everyone breathes in LPS, doesn't everyone develop asthma? In this new study, Bureau and colleagues believe they have discovered an important clue, because in mice they found that lung interstitial macrophages (IMs) prevented lung immune cells known as dendritic cells from triggering a Th2 immune response to LPS and an experimental harmless airborne antigen.
Microbe-derived molecules able to stimulate the immune system are omnipresent in the air, and the presence of one such molecule (LPS) promotes asthma in some individuals. What prevents inhalation of LPS from promoting asthma in the majority of individuals is not well understood. However, Fabrice Bureau and colleagues, at the University of LiÃ¨ge, Belgium, have now ascribed this function in mice to a population of lung immune cells known as lung interstitial macrophages (IMs). Surprisingly, this is the first in vivo function described for these cells. The way in which airborne LPS promotes asthma is by inducing lung immune cells known as DCs to initiate Th2 immune responses towards normally innocuous allergens. In the study, mouse IMs were found to produce high levels of the soluble immune factor IL-10, to inhibit LPS-induced DC activation in an IL-10-dependent manner, and to prevent the induction of Th2 responses directed towards innocuous allergens following exposure to LPS and the allergen.
Today at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology, Phadia US introduced two new products designed specifically to meet the unique needs of the nation's 6, 000 allergists. ImmunoCAP ISAC and ImmunoCAP HR are new offerings designed to augment traditional allergy testing methodologies and enable diagnosis of complex food allergies at the molecular level, available through its own PiRL testing facility. Immuno Solid-phase Allergy Chip, or ISAC, is a multi-array technology package designed to provide a detailed assessment of specific allergies as part of the initial patient assessment and workup. With ISAC, allergists can test for the particular molecular components driving the allergic disease process in patients. As a result, allergists can identify precisely those patients in danger of severe allergic reaction to allergens such as peanut, wheat, or egg and many others. ISAC uses a small sample of blood to produce results for 103 components representing a wide spectrum of allergens.
Occupational contact dermatitis and asthma are two of the most common work-related health issues facing workers worldwide, according to experts presenting the latest research at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla. "In many countries, occupational contact dermatitis ranks first among occupational diseases, " said Donald Belsito, M.D., clinical professor of dermatology at the University of Missouri in Kansas City, Mo. "The incidence of occupational contact dermatitis in the United States is underestimated by 10 to 50 times." Occupational contact dermatitis involves an acute or chronic inflammation of the skin from exposure to chemical, biological or physical agents in the workplace. According to Belsito, registries are incomplete and the incidence is underreported. Differences in reporting across countries further complicate data on its global prevalence. "After the skin, the lungs are the most commonly affected organ in the workplace, " said Emil J.
Food allergy is a serious and sometimes life-threatening health issue that is increasing among children of all ages, races and ethnicities. Reports indicate that food allergies, especially peanut allergies, are growing, but there is limited knowledge about diagnosis and treatment on a national basis. "Food Allergy Among Children in the United States, " published in the December issue of Pediatrics (appearing online Nov. 16), is the first study to describe trends in the prevalence of food allergy and food allergy-related health care in the U.S. According to the study, in addition to an 18 percent increase in the prevalence of self-reported food allergy, visits to ambulatory facilities related to food allergies nearly tripled between 1993-1997 and 2003-2006 from an estimated 116, 000 to 317, 000 visits per year. Researchers also found that in 2005-2006, 9 percent of U.S. children 1 to 17 years of age had positive serum immunoglobulin E antibodies to peanuts. Rates of food allergy among boys and girls were similar, but there were differences by race/ethnicity.
UC Irvine pharmacology researchers have discovered a way to boost levels of a natural body fat that helps decrease inflammation, pointing to possible new treatments for allergies, illnesses and injuries related to the immune system. For decades, it has been known that this fat, called palmitoylethanolamide (PEA), is a potent anti-inflammatory substance that reduces both allergic symptoms and occurrences of rheumatic fever, but researchers understood little about how PEA works. In a study appearing online in the Proceedings of the National Academy of Sciences, Daniele Piomelli, the Louise Turner Arnold Chair in Neurosciences at UCI, and colleagues found that levels of PEA are tightly regulated by immune system cells. In turn, PEA helps control the activity of these cells, which are called into action to fight infection, disease and injury in the body. In addition, they found that PEA - also present in foods like eggs and peanuts - is deactivated by a protein called N-acylethanolamine-hydrolyzing acid amidase, which is an enzyme that breaks down molecules controlling cell inflammation.
The estimated 4.6 million Americans involved in the equine industry may be at risk of developing respiratory symptoms due to poor air quality in horse barns, according to a questionnaire study undertaken earlier this year by investigators at Tufts University's Cummings School of Veterinary Medicine. The study - which polled more than 80 New England horse barn workers - found that 50 percent of individuals working in barns complained of coughing, wheezing, or other ailments in the last year, compared to just 15 percent in the control group of 74 people. Moreover, increased exposure to barns yielded higher rates of self-reported respiratory symptoms, the study reports. The study was published in the journal Occupational Medicine and funded by the National Institutes of Health. "It has long been known that lower respiratory illness is common in horses, and this is typically attributed to the amount of dust in barns, " said Melissa R. Mazan, DVM, associate professor of clinical sciences at the Cummings School and the study's lead author.